A$0.46 0.0 1.1%
Last Trade - 7:10am
| Market Cap | £424.4m |
| Enterprise Value | £547.3m |
| Revenue | £244.2m |
| Position in Universe | 339th / 1899 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 141.4 | 267.3 | 572.6 | 530.4 | 526.2 | 457.8 | 425 | 497 | +26.5% | ||
| -49.4 | +232.8 | +13.4 | -13.7 | +700 | ||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 18, 2005 |
| Public Since | June 29, 2007 |
| No. of Shareholders: | 17,484 |
| No. of Employees: | 850 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 1,679,068,131 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 1538 Main North Rd, ADELAIDE, 5106, Australia |
| Web | http://www.maynepharma.com/ |
| Phone | +61 8 82092666 |
| Contact | Lisa Pendlebury (IR Contact Officer) |
| Auditors | Ernst & Young |
As of 7:10am, shares in Mayne Pharma are trading at A$0.46, giving the company a market capitalisation of £424.4m. This share price information is delayed by 15 minutes.
Shares in Mayne Pharma are currently trading at A$0.46 and the price has moved by 42.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mayne Pharma price has moved by 8.24% over the past year.
Of the analysts with advisory recommendations for Mayne Pharma, there are there are currently 2 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mayne Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Mayne Pharma is scheduled to issue upcoming financial results on the following dates:
Mayne Pharma does not currently pay a dividend.
Mayne Pharma does not currently pay a dividend.
Mayne Pharma does not currently pay a dividend.
To buy shares in Mayne Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Mayne Pharma are currently trading at A$0.46, giving the company a market capitalisation of £424.4m.
Here are the trading details for Mayne Pharma:
Based on an overall assessment of its quality, value and momentum, Mayne Pharma is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Mayne Pharma are currently priced at A$0.46. At that level they are trading at 16.26% premium to the analyst consensus target price of 0.00.
Analysts covering Mayne Pharma currently have a consensus Earnings Per Share (EPS) forecast of 0.001 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mayne Pharma. Over the past six months, the relative strength of its shares against the market has been 20.92%. At the current price of A$0.46, shares in Mayne Pharma are trading at 29.16% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mayne Pharma PE ratio based on its reported earnings over the past 12 months is 22.17. The shares are currently trading at A$0.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mayne Pharma's management team is headed by:
Here are the top five shareholders of Mayne Pharma based on the size of their shareholding:
